Key Takeaways
- High interest rates and other macro issues continue to impact biopharma company valuations and investor interest, but specialist investors see reasons to back drug developers in 2025.
Biopharmaceutical companies looking to raise money in 2025 can expect more of the same as what they experienced in 2024,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?